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A B S T R A C T
Objective: Cardiovascular (CV) disease is leading cause of mortality in rheumatoid arthritis (RA).
Dysfunction of the vascular endothelium is a hallmark of most conditions that are associated with
atherosclerosis and is therefore an early feature in atherogenesis. Biomarkers for rapid evolution of CV
complications would be highly desirable for risk stratiﬁcation. Finally, predictive biomarkers for
cardiovascular risk would allow tailoring therapy to the individual. We assessed endothelial function
and atherosclerosis utilizing carotid intima-media thickness (CIMT) in RA in context of clinical and
laboratory markers in Indian RA population.
Methods: We performed a prospective study of 35 consecutive RA patients and 25 age- and sex matched
healthy controls. Patients with traditional CV risk factors were excluded. Flow mediated dilatation (FMD)
as measures of endothelial function and CIMT as measures of atherosclerosis were assessed. Disease-
speciﬁc measures, inﬂammatory measures, serum cytokines, serum nitrite, lipids and endothelial
progenitor cells (EPCs) were estimated.
Results: FMD was signiﬁcantly lower in RA (6.53%  1.81%) compared to controls (10.77%  0.53%;
p < 0.001). CIMT (mm) was signiﬁcantly increased in RA (0.62  0.17) vs. controls (0.043  0.07; p = 0.003).
In RA patients, FMD% inversely correlated with CIMT, CRP, DAS-28, TNF-a, serum nitrite and positively
correlated with EPC. CIMT correlated with age, DAS-28, IL-6, HDL, LDL, and inversely correlated with EPC.
Conclusions: In the present study, FMD and CIMT were impaired in RA, indicating endothelial
dysfunction and accelerated atherosclerosis respectively. CRP, TNF-a, serum nitrite, DAS-28 and
depleted EPC population predicted endothelial dysfunction. Age, IL-6, HDL, LDL and depleted EPC
population predicted accelerated atherosclerosis.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Rheumatoid arthritis (RA) is a chronic inﬂammatory, autoim-
mune disease that affects the synovial tissues, leading to cause
pain and joint destruction. The prevalence rate of RA in Indian
population is approximately 0.75% and it is quite similar to
developed countries.1 These ﬁndings are keeping with fact that
Indian population is genetically closer to the Caucasians than to
other ethnic groups.1 Patients with RA have a higher risk of
cardiovascular disease (CV); over the past decade it has become
clear that CV disease is the major cause of death in RA.2 Increased
cardiovascular risk in RA patients, as mortality is primarily due to* Corresponding author at: Healing Touch City Clinic, #547, Sector 16-D,
Chandigarh 160015, India.
E-mail address: ashitsyngle@yahoo.com (A. Syngle).
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Indian population, Indian Heart J. (2016), http://dx.doi.org/10.1016/j
http://dx.doi.org/10.1016/j.ihj.2016.10.013
0019-4832/ 2016 Published by Elsevier B.V. on behalf of Cardiological Society of
creativecommons.org/licenses/by-nc-nd/4.0/).CV events rather than disease per se.3 The increased cardiovascular
mortality risk in patients with RA cannot be entirely explained by
traditional CV risk factors, suggesting that the systemic inﬂamma-
tion that characterizes RA may cause endothelial dysfunction and
accelerate atherosclerosis.2 The expression of pro-inﬂammatory
cytokines and inﬂammatory mediators plays a crucial role in
atherosclerotic process in rheumatic patients.4
Endothelial dysfunction is a barometer of CV health an
important sign of early atherosclerosis and can be assessed non-
invasively by ﬂow mediated vasodilatation (FMD) of peripheral
arteries.5 Increased carotid intima-media thickness (CIMT), deter-
mined by high-resolution B-mode ultrasound,6 is regarded as an
early indicator of atherosclerosis and future cardiovascular
disease.7 Both methods are closely related to endothelial damage
and are early markers of atherosclerosis.8
There has been several studies has been shown altered
endothelial function and increased CIMT from other countries inhelial dysfunction and atherosclerosis in rheumatoid arthritis in
.ihj.2016.10.013
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the endothelial function and CIMT in RA patients from India.17–21
The prevalence of coronary artery disease (CAD) in Indian
population is nearly 10 times higher than that seen 40 years
ago.22 In a recent study, the prevalence of CAD in migrant Indians
in Canada was more than twice of that observed in the Caucasian
population.23 It has been demonstrated that both traditional and
nontraditional risk factors contribute to the pathogenesis of
cardiovascular disease in RA patients.
Thus, we examined the endothelial function and carotid intima-
media thickness in active RA patients from India who did not have
traditional cardiovascular risk factors with well matched healthy
individuals. We also measured disease activity, serum cytokines,
endothelial progenitor cells and serum nitrite and studied their
possible correlation with FMD and CIMT to evaluate the potential
risk factors for endothelial dysfunction and atherosclerosis related
to RA especially in the context of Indian population.
2. Materials and methods
2.1. Patients and control
We performed a prospective study of 35 consecutive RA patients
meeting 2010 Rheumatoid Arthritis Classiﬁcation Criteria,24Assessed for  eli
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Please cite this article in press as: Verma I, et al. Predictors of endot
Indian population, Indian Heart J. (2016), http://dx.doi.org/10.1016/jcompared with age and sex matched healthy controls (n = 25)
from among the clinic staff and patient attendants were recruited.
This study was carried out out-patient rheumatology clinic in
Chandigarh, India during October 2012 to March 2014. Written
informed consent was taken from all patients and the control group
and the Institutional Clinical Ethics Committee (ICEC) approved the
study protocol. In all of them, a detailed history was taken and a
trough physical examination and following laboratory investiga-
tions were carried out: complete blood count, fasting sugar and
HbA1c level, liver and kidney function test, serum lipids, urine
analysis and electrocardiogram (Fig. 1). Patients and controls having
known risk factors for atherosclerosis were excluded, including ages
between >18 and 60 years, did not have any other autoimmune
disease, diabetes mellitus as diagnosed according to World Health
Organization criteria (WHO, 1985), dyslipidemia (total cholesterol
240 mg/dl, low-density lipoprotein cholesterol 160 mg/dl), obesity
(body mass index 30) or hypothyroidism, past or present smokers,
renal insufﬁciency, liver disease. Coronary artery disease, stroke or
hypertension as deﬁned by blood pressure >140/90 mm Hg or
history of use of antihypertensive medication. Patients taking
medication likely to affect endothelial function (anti-TNF-a
inhibitors, beta blockers, angiotensin converting enzyme inhibitor,
angiotensin receptor blocker, statins, aldosterone antagonist,
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Table 1
Demographic, clinical and biochemical characteristics of the study subjects.
Variable Rheumatoid arthritis (n = 35) Healthy subjects (n = 25) p Value
Age (years) 46.0  9.1 42.8  7.6 0.15
Gender: M/F (n) 12/23 9/16 –
BMI (kg/m2) 24.1  3.9 23.2  2.6 0.30
Smoking (n) 0 0 –
Systolic BP (mm Hg) 125.0  20.9 118.8  8.7 0.16
Diastolic BP (mm Hg) 79.3.  8.3 76.4  8.4 0.27
Disease duration (years) 8.5  5.0 – –
Fasting glucose (mg/dl) 102.1  8.4 96.3  6.2 0.26
HbA1c (%) 5.44  0.4 5.26  0.7 0.23
Serum creatinine (mmol/l) 0.89  0.8 0.82  0.6 0.27
Total cholesterol (mg/dl) 166.6  18.8 162.2  15.7 0.42
HDL cholesterol (mg/dl) 42.4  3.3 44.1  3.8 0.09
LDL cholesterol (mg/dl) 95.9  15.9 89.49  11.86 0.26
Triglycerides (mg/dl) 121.5  26.7 118.2  20.3 0.45
ESR (mm 1st h) 36.64.  9.42 17.6  4.64 <0.001*
CRP (mg/dl) 13.09  8.26 3.98  1.14 <0.001*
DAS-28 4.10  0.64 – –
FMD% 6.53  1.81 10.77  0.53 <0.001*
CIMT (mm) 0.62  0.017 0.43  0.007 0.003*
EPC% 0.021  0.007 0.044  0.01 <0.001*
S. Nitrite 5.76  1.0 1.92  0.64 <0.01*
TNF-a (pg/ml) 4.02  0.89 3.13  0.99 <0.001*
IL-6 (pg/ml) 12.40  3.91 4.01  0.83 <0.001*
IL-1 (pg/ml) 243.8  59.5 88.72  17.9 <0.001*
Values are mean  SD.
* p-value <0.05.
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS-28, disease activity
score in 28 joints count; FMD, ﬂow mediated dilation; CIMT, carotid intima media thickness; EPCs, Endothelial progenitor cells; TNF-a, tumor necrosis factor-a; IL-6,
interleukin-6; IL-1, interleukin-1.
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characteristics are depicted in Table 1. RA patients were on stable
dose of combination of synthetic disease modifying anti-rheumatic
drugs (DMARDs) for at least 3 months prior to study enrollment.
2.2. Assessment of endothelial function
Subjects were studied in the morning, after overnight fasting, in
a quiet room with controlled temperature. With the subjects lying
supine and their arms in a comfortable position, we assessed
endothelial function by brachial artery ﬂow-mediated dilatation
(FMD) by using, AngioDefender (Everist Genomics, Ann Arbor, MI,
United States). The AngioDefender device uses a novel, proprietary
software algorithm to analyze pulse wave data collected before
and after Brachial Artery (BA) occlusion by an upper arm
sphygmomanometric cuff. At the end, of the testing procedure
(15 min), the maximal relative post-occlusion change in the
diameter of the BA relative to baseline is calculated and expressed
as a percentage of ﬂow mediated dilation (%FMD). AngioDefender
test results are not dependent on user technique or operator
proﬁciency.5 Mean of the two measures were considered for
analysis.
2.3. Assessment of carotid intima-media thickness
All subjects were examined using a high-resolution Doppler
ultrasound (HD 11 XE ultrasound machine, Philips Medical
System) using a 13–5 MHz linear array transducer in the supine
position. The CCA intima-media thickness (IMT) was deﬁned as the
average of the maximum IMT of the near and of the far wall
measurements in the distal CCA (1 cm proximal to the carotid
bulb). Intima media thickness was measured at three points on the
far walls of both the left and the right common carotid arteries
(CCA). The three locations were then averaged to produce the mean
IMT for each side. All images of the carotid arteries were recorded
on the hard disk of the ultrasound system for subsequent analysis
and evaluated by a well experienced radiologist who was blindedPlease cite this article in press as: Verma I, et al. Predictors of endot
Indian population, Indian Heart J. (2016), http://dx.doi.org/10.1016/jto the clinical characteristics of the participants.6 The subjects had
fasted overnight and they were studied in the morning between
9 and 11 AM.
2.4. Assessment of EPC population through ﬂow cytometry analysis
After patients and control subjects fasted overnight, peripheral
blood was taken at rest, in the morning, at forearm, together with
routine analysis. EPCs were quantiﬁed by ﬂuorescence-activated
cell sorting (FACS) calibur ﬂow cytometer (Canto II; BD Biosciences,
San Jose, CA).
FACS analysis was performed with utilization of the following
three markers:
1. Fluorescein isothiocyanate (FITC) anti-CD45 (BD Sciences, San
Jose, CA)
2. Phycoerythrin (PE) anti-CD34 (BD Sciences, San Jose, CA)
3. Allophycocyanin (APC) anti-CD133 (Miltenyi Biotec, Bergisch
Gladbach, Germany)
Peripheral blood in EDTA (200 mL) was labeled with a panel of
above mentioned antibodies and incubated for 1 h at room
temperature. After conjugation, red blood cells were lysed with
ammonium chloride for 15 min at room temperature. Thereafter,
cells were washed and resuspended in 500 ml phosphate buffered
saline (PBS; Seromed). Appropriate sequential analysis was used to
enumerate total EPCs and to exclude debris. Putative EPCs were
deﬁned as positive for anti-CD34 and anti-CD133. At least
250,000–500,000 cells per sample were acquired. Data were
analyzed with Cell Quest software (Becton Dickinson). Results are
expressed as % cells gated.25
2.5. Serum nitrite estimation
Nitric oxide was directly determined as nitrite by a spectro-
photometric method,26 using serum samples collected after
overnight fasting. Gaseous NO free radical is rapidly metabolizedhelial dysfunction and atherosclerosis in rheumatoid arthritis in
.ihj.2016.10.013
Fig. 2. Comparison between mean ﬂow mediated dilatation (FMD) of both patients
and controls.
Fig. 3. Comparison between mean carotid intima-media thickness (CIMT) of both
patients and controls.
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as an index of NO production. Nitrite is also not inﬂuenced by
dietary variation.10 Samples for serum nitrite were estimated in
duplicate. Mean of the two measured value was considered for
analysis.
2.6. Clinical and biochemical assessment
Patients underwent clinical evaluation at time of recruitment.
Disease activity was measured using the 28-joint disease activity
score (DAS28). Biochemical assessment including a complete
blood count, liver function tests, renal function test, vitamin B12,
thyroid stimulating hormone, blood sugar, HbA1c and ‘serum
lipids were determined using standard commercial kits and urine
analysis to detect proteinuria, hematuria and cellular casts.
Inﬂammatory markers i.e. Erythrocyte sedimentation rate (ESR)
was measured using Westergren method and C-reactive protein
(CRP) level using standard commercial kits. Inﬂammatory cyto-
kines; tumor necrosis factor (TNF)-a, interleukin (IL)-6 and IL-1
were also assessed in all subjects by enzyme-linked immunosor-
bent assays (Hiss Diagnostics GmbH, Freiburg, Switzerland). All
patients underwent clinical and biochemical assessment at the
time of recruitment. Clinical, biochemical, FMD and CIMT
assessments were carried out on the same day of recruitment
after overnight fasting. Blood samples drawn for determination of
serum cytokines and nitrite were stored at 80 8C before
laboratory testing.
2.7. Statistical analysis
Continuous data are expressed as the mean  standard devia-
tion (SD). Patients and healthy control subjects were compared using
unpaired Student’s t-test for continuous variables and chi-squared
test for categorical variables. Pearson correlation coefﬁcients were
calculated for RA patients to study the relationship between
endothelial function, CIMT and clinical and biochemical disease
variables. Two-sided p-values of less than 0.05 were considered
statistically signiﬁcant. The statistical analysis was carried out using
Sigmastat 5.5 for Windows 7.
3. Results
The recorded baseline characteristics in the RA patients and
healthy control individuals comprised traditional cardiovascular
risk factors are summarized in Table 1. There were no signiﬁcant
differences in age, sex, and mean BMI values between RA patients
and healthy controls. All study subjects were free from any
traditional cardiovascular risk factors and cardiovascular dis-
orders.
The clinical index of disease activity (DAS-28) was 4.10  0.64
(Table 1). There were signiﬁcant differences in the ESR and CRP levels
between the RA patients and the controls (both p < 0.001). The mean
serum level of proinﬂammatory cytokines i.e. TNF-a, IL-6 and IL-1 in
RA patients was higher than that in healthy controls (All p < 0.001,
Table 1). As regards the FMD (6.53  1.81% vs. 10.77  0.53%, Fig. 2),
CIMT (0.62  0.017 mm vs. 0.43  0.007 mm, p = 0.003, Fig. 3) and
EPC% (0.021  0.007 vs. 0.044  0.01, p < 0.001) revealed signiﬁcant-
ly abnormal values in RA patients compared with controls (Table 1).
Table 2 shows negative correlations between FMD% and CRP,
DAS-28, TNF-a, serum nitrite, as well as CIMT. In contrast,
signiﬁcant positive correlations were found between CIMT and
age, DAS-28, IL-6, HDL, as well as LDL. EPC level signiﬁcantly
correlated with FMD and CIMT. However, no signiﬁcant correlation
was demonstrated between FMD% and age, disease duration and
BMI. Moreover, there was no signiﬁcant correlation of CIMT with
disease duration and BMI.Please cite this article in press as: Verma I, et al. Predictors of endot
Indian population, Indian Heart J. (2016), http://dx.doi.org/10.1016/j4. Discussion
Patients with RA are more prone to accelerated atherosclerosis
and Asian Indians as an ethnic group are predisposed to a high risk
of premature atherosclerosis.27 Increased prevalence of endothe-
lial dysfunction and accelerated atherosclerosis has been reported
in Indian RA patients.17,18,20,21 However, there is sparse data
regarding the predictors of endothelial dysfunction and accelerat-
ed atherosclerosis among asymptomatic active RA patients in
Indian population.19 To the best of our knowledge, this is the ﬁrst
study to investigate the potential biomarkers of endothelial
dysfunction and accelerated atherosclerosis in active RA patients
in Indian population. These results may help to explain the
increased cardiovascular morbidity and mortality observed in RA
patients and possibly also acts as potential therapeutic targets to
prevent/treat CV risk in RA. Result of the present study
demonstrate that active RA patients in the absence of traditional
CV risk factors (hypertension, hypercholesterolemia, diabetes,
obesity and smoking) having altered endothelial function and
accelerated atherosclerosis exhibited by decreased FMD and
increased CIMT compared to age and sex matched healthy
controls. Increased level of CRP, TNF-a, serum nitrite, DAS-28
and depleted endothelial progenitor cells (EPCs) predicted
endothelial dysfunction. Increased age, IL-6, LDL, decreased HDL
level and depleted EPC population predicted accelerated athero-
sclerosis.
Results of our study implicate that FMD and CIMT were
signiﬁcantly higher in active RA patients in absence of CV risk
factors than that in healthy controls. Our result was the samehelial dysfunction and atherosclerosis in rheumatoid arthritis in
.ihj.2016.10.013
Table 2
Correlations of clinical, laboratory and inﬂammatory biomarkers with FMD and CIMT in RA patients.
FMD% CIMT
r value p Value 95% CI for mean r value p Value 95% CI for mean
Age 0.295 0.09 0.57–0.04 0.564 <0.001 0.27–0.75
BMI 0.07 0.660 0.40–0.26 0.152 0.39 0.46–0.19
DD 0.001 0.994 0.34–0.33 0.230 0.192 0.11–0.52
ESR 0.117 0.510 0.23–0.43 0.071 0.690 0.39–0.27
CRP 0.347 0.02 0.63–0.07 0.297 0.071 0.08–0.59
DAS-28 0.424 0.01 0.66–0.10 0.383 0.02 0.05–0.63
TNF-a 0.489 0.003 0.70–0.17 0.314 0.07 0.02–0.58
IL-6 0.267 0.127 0.55–0.07 0.344 0.04 0.007–0.61
IL-1 0.156 0.377 0.46–0.19 0.186 0.291 0.16–0.01
CIMT 0.387 0.02 0.64–0.05 – – –
EPC% 0.523 0.001 0.22–0.73 S0.352 0.04 0.61–0.01
S. Nitrite 0.342 0.04 0.60–0.03 0.122 0.491 0.22–0.44
TC 0.052 0.78 0.39–0.30 0.347 0.06 0.008–0.62
HDL 0.167 0.370 0.49–0.19 0.407 0.02 0.06–0.66
LDL 0.051 0.787 0.39–0.30 0.430 0.01 0.08–0.68
TG 0.107 0.566 0.25–0.44 0.272 0.13 0.09–0.57
Bold values are statistically signiﬁcant, p < 0.05. Values were calculated using Pearson’s correlation coefﬁcient. BMI, body mass index; DD, disease duration; ESR, erythrocyte
sedimentation rate; CRP, C-reactive protein; DAS-28, disease activity score in 28 joints count; TNF-a, tumor necrosis factor-a; IL-6, interleukin-6; IL-1, interleukin-1; CIMT,
carotid intima media thickness; EPCs, endothelial progenitor cells; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides.
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CIMT.11–14,17,18,20,21 Earlier evidence suggests that Caucasian
individuals without diabetes, chronic kidney disease or cardiovas-
cular events, who had long-standing RA exhibited of endothelial
dysfunction.9 An another classical study by Gonzalez-Juanatey
et al. has shown increased frequency of severe subclinical
atherosclerotic ﬁndings in long-term actively treated RA patients
without clinically evident atherosclerotic disease and absence of
classic CV risk factors from northwest Spain.10 In addition, a meta-
analysis of different studies conﬁrmed that CIMT is increased in
patients with RA.16 Impaired FMD and increased CIMT in DMARD
naive early RA patients has also been shown in Indian population
without clinically evident atherosclerotic disease.19 However, in
our study we have recruited those patients who have established
and active RA in the absence of CV risk factor and we also measured
inﬂammatory cytokines, serum nitrite and EPC population.
Early endothelial dysfunction indicated by FMD may precede
manifest atherosclerosis indicated by CIMT. Therefore, the more
pronounced endothelial dysfunction may lead to more accelerated
atherosclerosis.8 In conformity with this observation, FMD%
signiﬁcantly correlated with CIMT in our study when the. In this
regard, in Spanish individuals with RA, CIMT was negatively
associated with FMD when the time from disease diagnosis ranged
from 7.5 to 19.7 years.15
On Pearson correlation analysis, CRP, DAS-28, TNF-a, serum
nitrite and EPC population predicted endothelial dysfunction
independent of traditional cardiovascular risk factors. In our study
the level of CRP (13.09 mg/dl) is very high compared to the healthy
controls (3.98 mg/dl) and it signiﬁcantly correlated with FMD. It
has been shown that high level of CRP in RA is an independent
predictor for cardiovascular morbidity and mortality28 and it can
also develop a secondary immune cell activation, which may result
in atherogenesis.29
Earlier evidence suggests that endothelial dysfunction in RA
patients might be explained by disease activity measured by DAS-
28.11 Similarly, in our study we found signiﬁcant association
between disease activity and FMD suggesting that inﬂammation
plays a crucial role in the pathogenesis of cardiovascular disease in
patients with RA. TNF-a plays an important role in the initiation
and progression of inﬂammation in RA as well as in the
mechanisms implicated the accelerated atherosclerosis in these
patients.30 The proinﬂammatory cytokine, TNF-a also degrades
endothelial nitric oxide synthase (eNOS) mRNA and impaired NOPlease cite this article in press as: Verma I, et al. Predictors of endot
Indian population, Indian Heart J. (2016), http://dx.doi.org/10.1016/jbioavailability.31,32 This impaired NO bioavailability is a primary
manifestation of endothelial dysfunction, leading to impairment in
EDV.33 Multiple studies have demonstrated that endothelial nitric
oxide synthase (eNOS) protein expression is reduced via TNF-a
induced inhibition of eNOS promoter activity and mRNA desta-
bilization.32 A key role of TNF-a in atherosclerosis is supported by
the observation that biologic DMARD, anti TNF-a agent improves
endothelial dysfunction and improves atherosclerosis.34 A beneﬁ-
cial effect of combination of synthetic DMARDs (methotrexate
(MTX), hydroxychloroquine, and sulfasalazine) on FMD and CIMT
has been shown in RA patients.35 Our observations suggest that
increased level of TNF-a and serum nitrite signiﬁcantly linked with
FMD implicates that increased TNF-a and nitrite level as a
mediator of endothelial dysfunction in RA. We did not ﬁnd any
signiﬁcant correlation with IL-6 and IL-1. It may be due to the small
RA population. Dessein et al. reported that endothelial dysfunction
in RA was signiﬁcantly associated with IL-6 and suggested IL-6
known to be biomarker of endothelial dysfunction.13
In the current study we also measured EPCs and found depleted
EPC population in RA patients. EPCs are bone marrow derived stem
cells which have reparative potential in overcoming the endothe-
lial damage and protect against atherosclerotic vascular disease.36
Earlier, these cells have been studied in RA and recently studied by
us in ankylosing spondylitis (AS).25,36 Herbrig et al. have shown a
clear positive correlation between endothelial dysfunction and
depletion of EPCs.36 The study by Yiu et al. demonstrated that RA
patients with atherosclerosis have signiﬁcantly lower level of EPCs
than those without.37 The result of our study thus conﬁrmed that
EPCs population is closely associated with endothelial dysfunction
and increased CIMT and contributes to atherosclerosis in RA
patients.
CIMT was found to be positively correlated with age of the
patient in the present study suggesting that age is one of the risk
factor for carotid atherosclerotic disease. However, we did not ﬁnd
any correlation of CIMT with disease duration, ESR and CRP as it
was available in only 35 patients: therefore it did not assume
signiﬁcance, possibly due to low number of patients. Several
researchers provide evidence for greater CIMT with longer disease
duration,2,38 while others do not ﬁnd such an association.17,39 In a
study by Giles et al., increasing severity of RA was associated with a
high prevalence of increase of CIMT level.39 Similarly, in our study
we found signiﬁcant positive correlation between CIMT and
increased DAS-28 Score. We also found a signiﬁcant correlationhelial dysfunction and atherosclerosis in rheumatoid arthritis in
.ihj.2016.10.013
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HDL suggesting their role in the pathogeneses of atherosclerosis.
The role of proinﬂammatory cytokines IL-6 in the pathogen-
esis of RA has been well demonstrated. In the current study
we have found that IL-6 signiﬁcantly correlated with CIMT
level and this observation suggests the role of IL-6 in the
progression of atherosclerosis in patients with RA. Nunez,
et al. has shown increased level of IL-6 signiﬁcantly associated
with increased carotid IMT.40 Inhibition of IL-6 has been
reported to suppress atherogenesis in experimental animal
model.41 There are no human studies of the effects of IL-6
inhibition on atherosclerosis.
This study design had several strengths, notably analysis of well
characterized population and measurement of many inﬂammatory
biomarkers reported to be associated with endothelial dysfunction
and increased CIMT. The study also has its limitations, including
the cross-sectional design and the relatively low number of study
subjects. Therefore, we cannot exclude the possibility that markers
showing weaker, non signiﬁcant associations with atherosclerosis,
may also contribute to a relationship between inﬂammation and
atherosclerosis.
5. Conclusions
Our study on Indian patients have shown decreased FMD and
increased CIMT in well characterized RA population without
traditional cardiovascular risk factors, indicating early endothelial
dysfunction and accelerated atherosclerosis, respectively.
Our data suggest that early determination of FMD% and CIMT
may be useful tools to assess cardiovascular risk in RA. CRP, TNF-a,
serum nitrite, DAS-28 and depleted EPC population predicted
endothelial dysfunction. Age, IL-6, HDL, LDL and depleted EPC
population predicted accelerated atherosclerosis. Therapy that
effectively suppresses inﬂammation and stimulation of EPCs may
be beneﬁcial to prevent and manage early endothelial dysfunction
and accelerated atherosclerosis related to RA.
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